Multiple Sclerosis Research Repository

“Efficacy classification of modern therapies in multiple sclerosis”: Samjoo IA

-the ABN guidelines classified therapies based solely on relapse reduction and the NMA-based classification approach used in this study was not feasible for outcomes such as time to confirmed disability progression that are reported as relative values between DMTs.

– Our findings demonstrate that the relapse reduction associated with cladribine and ofatumumab is similar to other DMTs currently classified by the ABN as drugs of high efficacy. Ocrelizumab and ozanimod 1.0 mg were classified as moderate or high efficacy depending on the classification approach used, and ozanimod 0.5 mg was classified as moderate efficacy.